CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO™ (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L. We show 26 historical shares outstanding datapoints in our CTIC shares outstanding history coverage, used to compute CTIC market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing CTIC market cap history over the course of time is important for investors
interested in comparing CTIC's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of CTIC versus a peer is one thing; comparing
CTIC market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like CTIC can fluctuate over the course of history.
With this page we aim to empower investors researching CTIC by allowing them to research the CTIC market cap history. |
Free CTIC Email Alerts:
Video: The Importance of Market Cap
